骨关节炎
脂肪因子
抵抗素
医学
脂联素
瘦素
肥胖
发病机制
生物信息学
内科学
病理
胰岛素抵抗
生物
替代医学
作者
Chao Tu,Jieyu He,Bei Wu,Wanchun Wang,Zhihong Li
出处
期刊:Cytokine
[Elsevier]
日期:2019-01-01
卷期号:113: 1-12
被引量:50
标识
DOI:10.1016/j.cyto.2018.06.019
摘要
Osteoarthritis is the most prevalent form of aging-related joint diseases, and its etiology is still not fully understood. Obesity has been recognized as one of the most significant and potentially preventable risk factors for osteoarthritis. Beyond mechanical loading, adipokines, including leptin, visfatin, adiponectin, resistin and others, are demonstrated to have metabolic implications in the pathogenesis and progression in obesity-induced osteoarthritis by modulating the pro/anti-inflammatory and anabolic/catabolic balance, apoptosis, matrix remodeling and subchondral bone ossification. Accordingly, adipokines emerge as potential candidates to link these two entities, and may serve as putative targets for disease-modifying drugs for osteoarthritis, especially for obese patients. Here we summarize studies over the past decades on the pivotal role of adipokine family in osteoarthritis, and aim to shed a light on the causative link between obesity and osteoarthritis. Notably, due to difficulties in separation of the metabolic effect from the mechanical effect of fat excess, researches on osteoarthritis in non-weight-bearing joints may provide a promising direction and more emphasis shall be put on them in future.
科研通智能强力驱动
Strongly Powered by AbleSci AI